- Remove All
- Your shopping cart is currently empty
Most local anesthetics act by abolishing voltage gated sodium channel currents indiscriminately in all populations of neurons. Selective analgesia through TRPV1-mediated entry of a cationic lidocaine derivative, QX314, was recently reported. CAY10568 is a physically smaller, less hydrophobic version of QX314 designed to be even more permeable to TRPV1 ion channel when activated by agonists such as capsaicin and N-oleoyl dopamine. CAY10568 when given in combination with suitable TRPV1 agonists should produce selective blockade of the pain response while leaving motor, touch, and proprioception intact.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | $93 | 35 days | |
25 mg | $215 | 35 days | |
50 mg | $394 | 35 days | |
100 mg | $693 | 35 days |
Description | Most local anesthetics act by abolishing voltage gated sodium channel currents indiscriminately in all populations of neurons. Selective analgesia through TRPV1-mediated entry of a cationic lidocaine derivative, QX314, was recently reported. CAY10568 is a physically smaller, less hydrophobic version of QX314 designed to be even more permeable to TRPV1 ion channel when activated by agonists such as capsaicin and N-oleoyl dopamine. CAY10568 when given in combination with suitable TRPV1 agonists should produce selective blockade of the pain response while leaving motor, touch, and proprioception intact. |
Molecular Weight | 320.174 |
Formula | C11H17IN2O |
Cas No. | 22913-17-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | PBS (pH 7.2): 0.5 mg/mL DMF: 5 mg/mL DMSO: 3 mg/mL |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.